Global Metered-Dose Inhalers Market - 2025-2033

Global Metered-Dose Inhalers Market - 2025-2033

The global metered-dose inhalers market reached US$ 16.6 billion in 2023 and is expected to reach US$ 24.18 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033.

A metered-dose inhaler is a device that delivers medication into the lungs through a pressurized canister. It can be released manually or automatically when inhaled. Some inhalers have counters to track remaining doses. Dry powder inhalers (DPI) are breath-activated, releasing medication only when a deep, fast breath is taken through the inhaler.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

The market for metered dose inhalers (MDIs) is growing due to technological advancements. Modern MDIs feature integrated dose counters, smart connectivity, and breath-actuated mechanisms, addressing issues like improper dosage and patient adherence. These innovations are particularly beneficial for chronic conditions like asthma and COPD. The shift to environmentally friendly propellants aligns with global sustainability goals and ensures effective drug delivery. These improvements are enhancing user experience, safety, and therapeutic outcomes, driving demand for advanced MDIs.

For instance, in June 2024, Aseptika has launched the PUFFClicker3, a smart inhaler dose tracker compatible with both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI). The device supports 101 SNOMED-coded inhalers for both types, making inhaler switching a simple process. It provides graphical instructions for each inhaler, aiming to improve inhaler adherence for patients of all ages and respiratory conditions requiring inhaler treatment.

Stringent Regulatory Requirements

The global metered-dose inhalers market faces significant challenges due to stringent regulatory requirements from authorities like the FDA and EMA. These regulations mandate rigorous testing protocols to ensure safety, efficacy, and quality of MDIs. Transitioning to eco-friendly propellants has complicated the approval process, requiring extensive research and compliance measures. Delays in regulatory approvals can hinder product launches, impacting market dynamics. Variations in regulatory frameworks across regions also pose challenges for global expansion, creating barriers for both established and emerging players, limiting innovation and market growth.

Segment Analysis

The global metered-dose inhalers market is segmented based on product type, application, end user and region.

Product type:

Breath-Actuated Pressurized Inhalers segment is expected to dominate the metered-dose inhalers market share

The breath-actuated pressurized segment holds a major portion of the metered-dose inhalers market share and is expected to continue to hold a significant portion of the metered-dose inhalers market share during the forecast period.

Breath-actuated pressurized metered-dose inhalers (BAIs) are gaining prominence in the global MDI market due to their ability to address the challenge of coordination between inhalation and actuation. Traditional MDIs require patients to synchronize their breathing with the device's drug release, which can be difficult for certain populations, such as elderly patients and children. BAIs automatically release medication when the patient inhales, ensuring optimal drug delivery and improving therapeutic outcomes. They are particularly useful for chronic respiratory conditions like asthma and COPD, where long-term treatment compliance is crucial.

For instance, in November 2023, Berry Global Healthcare has introduced the PneumoHaler, a lightweight, breath-actuated inhaler designed for managing asthma and COPD. This multi-dose inhaler is designed to eliminate the need for pharmaceutical companies to develop their own platforms, allowing faster-to-market solutions. The PneumoHaler also improves medication administration by addressing poor user technique of pressurized metered dose inhalers.

Application:

Asthma segment is the fastest-growing segment in metered-dose inhalers market share

The asthma segment is the fastest-growing segment in the metered-dose inhalers market share and is expected to hold the market share over the forecast period.

Asthma is a major global market driver due to its high prevalence and the need for long-term management solutions. With over 260 Billion people affected by asthma, the demand for MDIs is increasing due to factors like urbanization, air pollution, and climate change. MDIs provide rapid drug delivery to the airways, relieving symptoms like wheezing and chest tightness. Advanced formulations, such as corticosteroids and combination therapies, have expanded treatment options. Government health initiatives and awareness campaigns support early diagnosis and management of asthma, further boosting demand for MDIs. Asthma's global burden directly influences the MDI market's growth trajectory.

For instance, in July 2023, Lupin has introduced Luforbec, a pressurized metered dose inhaler, for the treatment of asthma and COPD in Germany. Hormosan Pharma GmbH, a subsidiary of Lupin, has introduced Luforbec in the country. The product is suitable for adult asthma and COPD treatment, where an inhaled corticosteroid and long-acting beta2-agonist is used.

Geographical Analysis

North America is expected to hold a significant position in the metered-dose inhalers market share

North America holds a substantial position in the metered-dose inhalers market and is expected to hold most of the market share due to the rising prevalence of respiratory diseases like asthma and COPD in North America, combined with an aging population, has led to a greater need for effective treatment options. MDIs are one of the most commonly prescribed devices for managing these conditions. The high level of healthcare awareness, better access to medical facilities, and well-established healthcare infrastructure in the region support the demand for advanced inhaler technologies. Major pharmaceutical companies in North America continuously innovate to improve inhaler designs and formulations, including smart inhalers with dose counters and tracking capabilities, which improve patient compliance and make MDIs the treatment of choice for many.

For instance, according to National Heart, Lung and Blood Institute, COPD, a combination of emphysema and chronic bronchitis, affects over 14 billion adults in the US, with over half being women. The severity of each condition varies. COPD rates are higher in American Indian and Alaska Native communities and rural areas. It is a major cause of disability and the sixth leading cause of death in the US, according to the Centers for Disease Control and Prevention.

Europe is growing at the fastest pace in the metered-dose inhalers market

Europe holds the fastest pace in the metered-dose inhalers market and is expected to hold most of the market share due to the FDA approvals, increasing prevalence of respiratory diseases like asthma and COPD. The aging population and increased exposure to environmental pollutants contribute to this demand. The European Union's strict regulatory standards, focusing on eco-friendly propellants and sustainability, are driving innovation in the inhaler market. Government initiatives promoting early diagnosis and effective management of these diseases further support MDI demand. Healthcare reimbursement systems in Europe ensure patients have access to necessary treatments, including MDIs.

For instance, in January 2024, Avillion LLP, a drug development company, has received FDA approval for AstraZeneca's Airsupra, a first-in-class, pressurised metered-dose inhaler (pMDI) and rescue medication. Airsupra is designed to treat bronchoconstriction and reduce exacerbations in people aged 18 and older with asthma. The FDA approved Airsupra, which contains albuterol and budesonide, a short-acting beta2-agonist.

Moreover, the region's focus on medical technology and collaborations between healthcare institutions and pharmaceutical companies has led to continuous improvements in MDI design, enhancing user experience and therapeutic efficacy.

Competitive Landscape

The major global players in the metered-dose inhalers market include Sunovion Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim, Covis Pharma B.V., GlaxoSmithKline, Kindeva Drug Delivery LP, Teva Phamrmaceuticals, Norton Waterford LTD, Armstrong Pharmaceuticals Inc, Cipla LTD and among others.

Key Developments
• In November 2023, GSK plc is set to begin Phase III trials of a low carbon version of its metered dose inhaler, Ventolin (salbutamol), in 2024. If successful, it could reduce greenhouse gas emissions by around 90%, contributing to GSK's net-zero climate targets. The inhaler, used by 35 Billion patients worldwide, accounts for 49% of GSK's carbon footprint and contributes to global health systems' carbon footprint. Reducing the propellant's carbon footprint is a key milestone in the company's journey to net zero.
• In September 2024, AstraZeneca has completed studies for the transition of Breztri/Trixeo Aerosphere, a triple-combination therapy for chronic obstructive pulmonary disease, to a new propellant with 99.9% lower Global Warming Potential than current inhaled medicines. Breztri will be the first medicine in AstraZeneca's pressurised-metered dose inhalers (pMDIs) to transition to the new propellant. Clinical programs are underway for the transition of AstraZeneca's wider pMDI portfolio.

Emerging Players

The emerging players in the metered-dose inhalers market include Propeller Health (digital inhaler technology), Adherium (smart inhaler systems), Amiko Digital Health Limited and among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global metered-dose inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.